Expand KURA Menu
KURA MENU

KURA Latest Press Releases

-- September 4, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- September 1, 2026 --

Kura Oncology to Participate in Three Investor Conferences in September Globe Newswire 7:15 AM

-- August 12, 2026 --

Kura Oncology Reports Second Quarter 2026 Financial Results Globe Newswire 4:02 PM

-- August 10, 2026 --

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity Globe Newswire 8:32 AM

-- August 7, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- August 5, 2026 --

Kura Oncology to Report Second Quarter Financial Results Globe Newswire 7:30 AM

-- July 27, 2026 --

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Nave Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 Globe Newswire 6:32 AM

-- July 14, 2026 --

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026 Globe Newswire 7:02 AM

-- July 3, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- June 11, 2026 --

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML Globe Newswire 8:02 AM

-- June 5, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- June 3, 2026 --

Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy Globe Newswire 6:53 AM

-- June 2, 2026 --

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML Globe Newswire 8:32 AM

-- May 26, 2026 --

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors Globe Newswire 6:02 AM

-- May 19, 2026 --

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit Globe Newswire 4:02 PM

-- May 12, 2026 --

Kura Oncology Reports First Quarter 2026 Financial Results Globe Newswire 4:02 PM
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress Globe Newswire 9:40 AM

-- May 6, 2026 --

Kura Oncology to Participate in Bank of America Securities Healthcare Conference Globe Newswire 7:30 AM

-- May 5, 2026 --

Kura Oncology to Report First Quarter 2026 Financial Results Globe Newswire 7:30 AM

-- May 4, 2026 --

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- April 24, 2026 --

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML Globe Newswire 8:00 AM

-- April 17, 2026 --

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib Globe Newswire 6:00 AM

-- April 9, 2026 --

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes